Implications of the complex genomic landscape of RCC for targeted therapy and immunotherapy
This article discusses the multiple gene changes (genetic heterogeneity) found [...]
Papillary renal cell carcinoma has reduced cancer-specific mortality post-surgery
A study conducted by researchers at the Mannheim Medical Centre [...]
Results from the IMmotion 150 clinical trial comparing atezolizumab with sunitinib
In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, [...]
The role of cabozantinib in the first-line treatment of kidney cancer
Dr Toni Choueiri, from the Dana-Farber Cancer Institute in Boston, [...]
Outcomes after cryoablation versus nephrectomy
Percutaneous cryoablation (cryotherapy) is emerging as an alternative to partial [...]
Majority of recently-approved cancer treatments lack survival benefits
A study published in the British Medical Journal (BMJ) states that two [...]
Neoadjuvant treatment with sunitinib improves overall survival in people with metastatic kidney cancer
In this interview, Dr Daniel George from the Duke Cancer [...]
Promising new front-line treatments for advanced kidney cancer
In an interview with OncLive during the 2017 State of the Science [...]
